Home Tags NSCLC

Tag: NSCLC

Preclinical Data Highlights the Differentiating Properties of MYTX-011

Preclinical data highlighting the differentiating properties of Mythic Therapeutics' investigational cMET-targeting antibody-drug conjugates (ADC), MYTX-011, published in April 30, 2024 edition of Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR), demonstrated that this novel ADC which leverages Mythic’s innovative FateControl™ technology, actively navigated inside of cells, potentially increasing delivery of anti-cancer agents to tumor cells with less impact on healthy cells.

Phase 2 LUMINOSITY Study Shows Positive Results for Telisotuzumab Vedotin in...

Phase 2 LUMINOSITY Study Shows Positive Results for Telisotuzumab Vedotin in for Patients with Previously Treated Non-Small Cell Lung Cancer

What to Expect at ASCO ’23: Mythic Therapeutics’ MYTX-011 Trial In...

During the annual meeting of the American Society of Clinical Oncology (ASCO) held June 2-6, 2023 in Chicago, Illinois, and online, cancer researchers and...

Daiichi Sankyo and AstraZeneca Sign Collaboration with Lung Cancer Research Foundation;...

The Lung Cancer Research Foundation (LCRF), a leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve...

Combinations with Datopotamab Deruxtecan Show Promising Clinical activity in Treatment of...

Initial results from the TROPION-Lung02 Phase Ib trial demonstrated that that datopotamab deruxtecan (Dato-DXd), a specifically designed TROP2-directed DXd antibody drug conjugate (ADC) being...

Patritumab Deruxtecan Shows Tumor Response Across Multiple Resistance Mechanisms in Patients...

New data presented at this year’s annual meeting of the American Society of Clinical Oncology, held online June 4 - 8, 2021, confirms promising...

Phase I Dose Escalation Study with Mersana’s XMT-1592 Doses First Patient

Clinical-stage biopharmaceutical company Mersana Therapeutics has confirmed that a first patient has been dosed in a Phase I dose-escalation study evaluating XMT-1592. XMT-1592 is the...

WCLC 2019: Daiichi Sankyo to Present Late-breaking Results from U3-1402 and...

The World Health Organization (WHO) estimates that lung cancer causes 1.59 million deaths globally per year. Non-small cell lung cancer (NSCLC) accounts for 80%–90%...
General Views of the 55th Annual Meeting meeting of the American Society of Clinical Oncology. Photo Courtesy: © ASCO/Nick Agro 2019.

Preliminary Phase I Data for U3-1402 Shows Manageable Safety and Reduction...

Preliminary results from the dose escalation part of the phase I study with U3-1402, an investigational and potential first-in-class HER3 targeting antibody-drug conjugate or...

Updated Results for [Fam-] Trastuzumab Deruxtecan in Patients with HER2 Mutated...

Updated phase I safety and efficacy data for trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC) being developed by Daiichi...

X